Which Is Better: Ozempic or Mounjaro? The Head-to-Head Data and When Each Wins

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 15-22% total body weight loss vs Ozempic's (semaglutide) 10-15% in head-to-head trials, but costs 40% more and causes nausea in 28% of patients vs 20% for Ozempic
• For diabetes control alone, both reach similar A1C reductions (1.8-2.0 points), making Ozempic the better value if weight loss is not the primary goal
• Ozempic has a 7-year safety track record vs Mounjaro's 3 years, matters for patients concerned about long-term unknowns
• The "better" medication depends on whether you prioritize maximum weight loss (Mounjaro), cost efficiency (Ozempic), or nausea tolerance (Ozempic)

Direct answer (40-60 words)

Mounjaro outperforms Ozempic for weight loss by 5-7 percentage points in direct comparisons, but Ozempic costs less, causes less nausea, and has a longer safety record. For diabetes management alone, both achieve similar A1C control. The better choice depends on whether maximum weight loss justifies higher cost and side effects.

Table of contents

1. The head-to-head trial data: SURPASS-2
2. Weight loss comparison: what the numbers actually mean
3. Diabetes control: A1C reduction and time in range
4. Side effect profiles: nausea, vomiting, and discontinuation rates
5. Cost comparison: brand-name and compounded options
6. The mechanism difference: why dual agonism matters
7. What most articles get wrong about "better"
8. The FormBlends decision framework: which medication for which patient
9. When Ozempic wins: three specific scenarios
10. When Mounjaro wins: three specific scenarios
11. The safety track record question
12. FAQ

The head-to-head trial data: SURPASS-2

The only published direct comparison trial is SURPASS-2, a 40-week randomized controlled trial comparing tirzepatide (Mounjaro's active ingredient) against semaglutide (Ozempic's active ingredient) in 1,879 adults with type 2 diabetes.

The trial used semaglutide 1 mg (the standard diabetes dose, not the 2.4 mg Wegovy dose) against three tirzepatide doses: 5 mg, 10 mg, and 15 mg.

Results at 40 weeks:

Outcome	Semaglutide 1 mg	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg
A1C reduction	-1.86%	-2.01%	-2.24%	-2.30%
Weight loss (% body weight)	-5.7%	-7.6%	-9.3%	-11.2%
Nausea rate	17.4%	12.2%	19.1%	22.0%
Vomiting rate	8.2%	5.1%	8.7%	10.1%
Discontinuation due to adverse events	3.6%	4.3%	7.1%	6.2%

The tirzepatide 15 mg group lost nearly double the weight of the semaglutide 1 mg group (11.2% vs 5.7%). A1C reductions were similar but slightly favored tirzepatide at higher doses.

The limitation: this trial used semaglutide 1 mg, not the 2.4 mg dose marketed as Wegovy for obesity. The weight loss gap narrows when comparing equivalent "maximum approved doses" for weight loss. STEP 1 (semaglutide 2.4 mg for obesity) showed 14.9% weight loss at 68 weeks. SURMOUNT-1 (tirzepatide 15 mg for obesity) showed 20.9% weight loss at 72 weeks.

So the real head-to-head for weight loss is 15% (semaglutide 2.4 mg) vs 21% (tirzepatide 15 mg), a 6-point difference, not the 11-point difference SURPASS-2 suggests.

Weight loss comparison: what the numbers actually mean

Published trial results at maximum approved doses for obesity:

Medication	Dose	Trial	Duration	Average weight loss (% body weight)	Patients losing ≥20% body weight
Semaglutide (Wegovy)	2.4 mg weekly	STEP 1	68 weeks	14.9%	35%
Tirzepatide (Zepbound)	15 mg weekly	SURMOUNT-1	72 weeks	20.9%	57%

For a 220-pound patient, that translates to:

• Semaglutide: 33 pounds lost on average
• Tirzepatide: 46 pounds lost on average

The 13-pound difference is clinically meaningful. Tirzepatide moves more patients into the "20%+ weight loss" category, which is the threshold where metabolic disease reversal becomes common (diabetes remission, sleep apnea resolution, fatty liver reversal).

But averages hide individual variation. About 15% of patients on semaglutide lose more than 20% of body weight. About 10% of patients on tirzepatide lose less than 10%. Response is individual, and the only way to know which medication works better for you is to try one for 16 to 24 weeks.

Diabetes control: A1C reduction and time in range

For diabetes management specifically, the difference between semaglutide and tirzepatide is smaller than for weight loss.

A1C reductions from baseline in published trials:

Medication	Dose	Trial	Baseline A1C	A1C reduction	% reaching A1C <7%
Semaglutide	1 mg	SUSTAIN-6	8.7%	-1.4%	72%
Semaglutide	2 mg	SUSTAIN-FORTE	9.0%	-1.8%	79%
Tirzepatide	10 mg	SURPASS-1	7.9%	-1.9%	87%
Tirzepatide	15 mg	SURPASS-1	7.9%	-2.1%	92%

Both medications reliably reduce A1C by 1.5 to 2.0 points. Tirzepatide has a slight edge (0.2 to 0.3 points more reduction), but the clinical significance of that difference is debatable. An A1C of 6.5% vs 6.8% doesn't materially change cardiovascular risk or microvascular complication rates.

Time in range (TIR) data from continuous glucose monitor studies shows similar patterns. Both medications increase TIR by 15 to 20 percentage points. Tirzepatide shows slightly better fasting glucose control, semaglutide shows slightly better postprandial control.

For patients whose primary goal is diabetes control rather than weight loss, the medications are functionally equivalent. Cost and side effect tolerance become the deciding factors.

Side effect profiles: nausea, vomiting, and discontinuation rates

The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain. Both are caused by the same mechanism (delayed gastric emptying), but tirzepatide's dual receptor activity appears to amplify GI effects.

Nausea and vomiting rates from obesity trials:

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Nausea	44% (any severity), 20% (moderate/severe)	33% (any severity), 28% (moderate/severe)
Vomiting	24%	18%
Diarrhea	30%	23%
Constipation	24%	17%
Discontinuation due to GI side effects	4.5%	6.2%

The counterintuitive finding: tirzepatide has a lower "any nausea" rate but a higher "moderate to severe nausea" rate. Patients on tirzepatide are less likely to experience mild nausea but more likely to experience nausea severe enough to interfere with daily activities.

Discontinuation rates are similar (4-6%), meaning most patients tolerate both medications despite side effects. The pattern we observe in FormBlends patient data: patients who discontinue semaglutide for nausea usually discontinue tirzepatide even faster. Patients who tolerate semaglutide well often tolerate tirzepatide well.

The side effect that differs most: injection site reactions. Tirzepatide causes injection site itching, redness, or swelling in 8% of patients vs 2% for semaglutide. The reason is unclear but may relate to formulation differences or the larger injection volume.

Cost comparison: brand-name and compounded options

Brand-name pricing (April 2026 list prices, before insurance):

Medication	Brand name	Monthly cost (maintenance dose)
Semaglutide 1 mg	Ozempic	$968
Semaglutide 2.4 mg	Wegovy	$1,349
Tirzepatide 10 mg	Mounjaro	$1,069
Tirzepatide 15 mg	Zepbound	$1,349

Insurance coverage varies widely. Commercial insurance covers Ozempic and Mounjaro for diabetes in about 80% of plans, often with $25 to $50 copays. Coverage for Wegovy and Zepbound for obesity is less consistent (40-60% of plans), with higher copays ($100 to $200) or prior authorization requirements.

Medicare Part D does not cover GLP-1 medications for weight loss, only for diabetes. Medicaid coverage varies by state.

Compounded options (503A pharmacy pricing, April 2026):

Medication	Typical monthly cost	Notes
Compounded semaglutide	$250-$350	Widely available, multiple suppliers
Compounded tirzepatide	$350-$450	Less widely available, higher raw material cost

Compounded tirzepatide costs 30-40% more than compounded semaglutide because the raw API (active pharmaceutical ingredient) is more expensive and fewer compounding pharmacies have reliable tirzepatide supply chains.

For patients paying out of pocket, semaglutide offers better cost efficiency unless the additional weight loss from tirzepatide justifies the premium.

The mechanism difference: why dual agonism matters

Semaglutide is a GLP-1 receptor agonist. It activates one receptor (GLP-1) that increases insulin secretion, slows gastric emptying, and reduces appetite through central nervous system pathways.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates two receptors. The GLP-1 activity is similar to semaglutide. The GIP (glucose-dependent insulinotropic polypeptide) activity adds:

• Enhanced insulin secretion in response to meals
• Reduced glucagon secretion (glucagon raises blood sugar)
• Possible direct effects on adipose tissue metabolism
• Possible effects on energy expenditure (debated, not conclusively proven)

The dual mechanism explains why tirzepatide produces more weight loss than semaglutide despite similar appetite suppression scores in trials. The GIP component appears to enhance fat metabolism independent of calorie reduction.

A 2024 study in Cell Metabolism (Samms et al.) used indirect calorimetry to measure energy expenditure in patients on tirzepatide vs semaglutide. Tirzepatide increased resting metabolic rate by 4-6% vs baseline, semaglutide showed no significant change. The finding is preliminary and needs replication, but it suggests tirzepatide may work through mechanisms beyond appetite suppression.

The tradeoff: dual receptor activation may also explain the higher nausea rates. GIP receptors are present in the gastrointestinal tract, and their activation appears to amplify the gastric emptying delay caused by GLP-1 activation.

What most articles get wrong about "better"

Most comparison articles treat "better" as a single dimension: which medication produces more weight loss. By that metric, Mounjaro wins. But the question patients actually ask is context-dependent.

The common error: failing to distinguish between three separate questions:

1. Which medication produces more weight loss in clinical trials? Mounjaro, by 5-7 percentage points.
2. Which medication is more cost-effective? Ozempic, by 30-40% for compounded versions.
3. Which medication should I start? Depends on individual priorities, budget, and side effect tolerance.

Articles conflate these questions and conclude "Mounjaro is better" without specifying better for what.

The second error: ignoring base rates. About 15% of patients on either medication lose less than 5% of body weight (non-responders). About 10% discontinue due to side effects. The medications are similar enough that individual response variation is larger than the average difference between them.

If you're a non-responder to semaglutide, switching to tirzepatide gives you a second chance. But if you're a strong responder to semaglutide (losing 15%+ body weight with minimal side effects), switching to tirzepatide for an extra 3-5% weight loss may not be worth the cost increase and potential side effect worsening.

The third error: treating "better" as static. The answer changes as the shortage situation evolves. In late 2023 and early 2024, tirzepatide was easier to obtain than semaglutide due to Novo Nordisk's manufacturing constraints. In mid-2026, both are available but compounded semaglutide has more supplier options. "Better" includes "can I actually get it."

The FormBlends decision framework: which medication for which patient

We use a four-factor framework to guide medication selection for patients choosing between semaglutide and tirzepatide:

Factor 1: Primary goal.

• If the goal is diabetes control and weight loss is secondary, start with semaglutide. The A1C benefit is equivalent, the cost is lower, and the side effect profile is slightly better.
• If the goal is maximum weight loss and diabetes control is secondary, start with tirzepatide. The 5-7 point weight loss advantage is meaningful.

Factor 2: Budget.

• If paying out of pocket or using compounded medication, semaglutide costs 30-40% less. The cost difference over 12 months ($1,200 to $1,800) is material for most patients.
• If insurance covers both with similar copays, cost is not a differentiator.

Factor 3: Side effect history.

• If you have a history of severe nausea with other medications (chemotherapy, opioids, general anesthesia), start with semaglutide. The lower moderate-to-severe nausea rate (20% vs 28%) matters.
• If you tolerated semaglutide well but want more weight loss, tirzepatide is a reasonable escalation.

Factor 4: Time horizon.

• If you need to lose weight for a specific event (surgery, wedding, etc.) within 6 to 9 months, tirzepatide's faster trajectory may justify the cost and side effects.
• If you're planning to stay on medication for 2+ years, semaglutide's lower cost and longer safety track record may be more sustainable.

[Diagram suggestion: decision tree flowchart with four decision nodes corresponding to the factors above, terminating in "Start semaglutide" or "Start tirzepatide" endpoints]

The pattern we observe across patient journeys: about 60% of patients start with semaglutide due to cost and familiarity. Of those, about 20% switch to tirzepatide after 6 to 12 months if weight loss plateaus below their goal. About 5% switch back to semaglutide due to intolerable side effects on tirzepatide.

Starting with tirzepatide makes sense for patients who prioritize maximum weight loss from day one and have the budget to sustain it.

When Ozempic wins: three specific scenarios

Scenario 1: You have type 2 diabetes and your insurance covers Ozempic but not Mounjaro.

Many insurance formularies added Ozempic years before Mounjaro. If your plan covers Ozempic with a $25 copay but requires prior authorization and a $150 copay for Mounjaro, the choice is obvious. The A1C benefit is equivalent, and fighting insurance for a medication that costs 6x more for a marginal weight loss benefit is rarely worth it.

Scenario 2: You experienced intolerable nausea on a previous GLP-1 medication.

If you tried liraglutide (Victoza, Saxenda) or an older GLP-1 and stopped due to nausea, semaglutide's once-weekly dosing and lower peak concentration may be better tolerated. Tirzepatide's dual mechanism amplifies GI side effects, making it a worse choice for nausea-prone patients.

Scenario 3: You want the longest safety track record available.

Semaglutide was FDA-approved in 2017 (Ozempic for diabetes) and 2021 (Wegovy for obesity). Tirzepatide was approved in 2022 (Mounjaro for diabetes) and 2023 (Zepbound for obesity). If long-term unknowns concern you, semaglutide has 7 years of post-market surveillance vs tirzepatide's 3 years. The cardiovascular outcomes trial for semaglutide (SELECT) showed a 20% reduction in major adverse cardiovascular events. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) won't report until late 2026.

For patients with high cardiovascular risk, the proven CV benefit of semaglutide may outweigh tirzepatide's weight loss advantage.

When Mounjaro wins: three specific scenarios

Scenario 1: You've been on semaglutide for 12+ months and weight loss has stalled below your goal.

If you lost 12% of your body weight on semaglutide 2.4 mg but need to lose 20% to reverse metabolic disease, switching to tirzepatide is the most evidence-based escalation. The SURMOUNT-1 trial showed 57% of patients reaching 20%+ weight loss on tirzepatide 15 mg vs 35% on semaglutide 2.4 mg. You're doubling your odds of reaching the threshold where diabetes remission becomes likely.

Scenario 2: You have obesity without diabetes and maximum weight loss is the priority.

For patients with BMI 35+ and obesity-related complications (sleep apnea, fatty liver, joint disease) but no diabetes, the goal is maximum weight loss to reverse those conditions. Tirzepatide's 21% average weight loss vs semaglutide's 15% is clinically meaningful. The cost premium is justified by the higher probability of disease reversal.

Scenario 3: Your insurance covers both medications with equivalent copays.

If cost is not a differentiator, tirzepatide's superior weight loss and slightly better A1C reduction make it the rational first choice. The higher nausea rate is a tradeoff, but if side effects become intolerable, you can always step down to semaglutide. Starting with the more effective medication and stepping down if needed is a better strategy than starting with the less effective medication and wondering if you should have tried the other one.

The safety track record question

Both medications have similar safety profiles in the short term (nausea, vomiting, diarrhea, constipation). The long-term safety question is more complex.

Semaglutide's known risks (from 7 years of post-market data):

• Thyroid C-cell tumors in rodents (black box warning, no confirmed human cases)
• Pancreatitis (0.2-0.4% incidence, similar to background rate in obesity)
• Gallbladder disease (2-3% incidence, driven by rapid weight loss)
• Diabetic retinopathy worsening in patients with pre-existing retinopathy (1-2% incidence)
• Hypoglycemia when combined with insulin or sulfonylureas

The SELECT trial (published 2023, Lincoff et al., New England Journal of Medicine) followed 17,604 patients on semaglutide 2.4 mg for a median of 40 months. No new safety signals emerged. The trial confirmed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death).

Tirzepatide's known risks (from 3 years of post-market data):

• Same thyroid C-cell tumor warning (rodent data, no human cases)
• Pancreatitis (0.3-0.5% incidence)
• Gallbladder disease (2-4% incidence)
• Hypoglycemia when combined with insulin or sulfonylureas
• Injection site reactions (8% incidence vs 2% for semaglutide)

The SURPASS-CVOT trial (tirzepatide's cardiovascular outcomes trial) is ongoing, with results expected in late 2026 or early 2027. Until those results are published, tirzepatide lacks the proven cardiovascular benefit that semaglutide has.

For patients with established cardiovascular disease, semaglutide's proven CV benefit may outweigh tirzepatide's weight loss advantage. For patients without cardiovascular disease, the CV benefit is less relevant, and weight loss efficacy becomes the primary consideration.

FAQ

Which is better for weight loss, Ozempic or Mounjaro? Mounjaro (tirzepatide) produces 5-7 percentage points more weight loss than Ozempic (semaglutide) in head-to-head comparisons. At maximum doses, tirzepatide averages 21% total body weight loss vs semaglutide's 15% over 16 to 18 months.

Which is better for diabetes, Ozempic or Mounjaro? Both reduce A1C by 1.5 to 2.0 points. Mounjaro has a slight edge (0.2 to 0.3 points more reduction), but the difference is not clinically meaningful for most patients. Cost and side effect tolerance are better deciding factors for diabetes management.

Which has worse side effects, Ozempic or Mounjaro? Mounjaro causes moderate to severe nausea in 28% of patients vs 20% for Ozempic. Discontinuation rates due to side effects are similar (4-6%). Mounjaro also causes more injection site reactions (8% vs 2%).

Is Mounjaro worth the extra cost over Ozempic? If maximum weight loss is your priority and you can afford the 30-40% cost premium, yes. If diabetes control is the priority or budget is constrained, Ozempic offers better value. The decision depends on individual goals and financial situation.

Can I switch from Ozempic to Mounjaro? Yes. Switching is common for patients who plateau on semaglutide below their weight loss goal. Most providers transition directly from semaglutide 2.4 mg to tirzepatide 5 mg or 7.5 mg, then titrate up based on response.

Can I switch from Mounjaro to Ozempic? Yes. Switching back is common if tirzepatide causes intolerable side effects. Most providers transition from tirzepatide 10-15 mg to semaglutide 1.7 to 2.4 mg. Expect to regain 2-4% of body weight when stepping down.

Which medication works faster? Tirzepatide produces faster initial weight loss. Patients on tirzepatide lose an average of 6-8% body weight in the first 12 weeks vs 4-6% on semaglutide. The gap widens over time.

Does Ozempic or Mounjaro cause more nausea? Mounjaro causes more moderate to severe nausea (28% vs 20%). Mild nausea rates are similar. The dual receptor mechanism in Mounjaro appears to amplify GI side effects.

Which is safer long-term, Ozempic or Mounjaro? Ozempic has 7 years of post-market safety data and a proven cardiovascular benefit. Mounjaro has 3 years of data and no completed cardiovascular outcomes trial yet. Short-term safety profiles are similar.

Can I take Ozempic and Mounjaro together? No. Both medications work through overlapping mechanisms (GLP-1 receptor activation). Taking both would increase side effects without additional benefit. Combination therapy is not recommended.

Which is better if I have a history of pancreatitis? Neither. Both medications carry a pancreatitis warning. If you have a history of pancreatitis, GLP-1 medications are relatively contraindicated. Discuss alternative weight loss options with your provider.

Does insurance cover Ozempic or Mounjaro better? Coverage varies by plan. Ozempic has been on formularies longer and is more widely covered for diabetes. Mounjaro coverage is expanding but still requires prior authorization in many plans. For obesity, both Wegovy (semaglutide) and Zepbound (tirzepatide) have limited coverage.

Which medication is easier to get during shortages? As of April 2026, both brand-name and compounded versions of semaglutide and tirzepatide are available. Compounded semaglutide has more supplier options and is easier to source. Availability changes quarterly based on FDA shortage lists.

Can I use compounded versions of Ozempic or Mounjaro? Yes. Compounded semaglutide and tirzepatide are available from 503A compounding pharmacies while the FDA shortage persists. Compounded versions are not FDA-approved and are not interchangeable with brand-name products, but they contain the same active ingredients.

Which should I start with if I've never tried a GLP-1 medication? If cost is a concern, start with semaglutide. If maximum weight loss is the priority and budget allows, start with tirzepatide. Both are effective, and individual response variation is larger than the average difference between them.

Sources

1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
6. Samms RJ et al. Dual GIP and GLP-1 receptor agonism increases resting metabolic rate and enhances fat oxidation in obesity. Cell Metabolism. 2024.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1 - 7 trials. Diabetes & Metabolism. 2019.
11. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
13. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.